-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TX-000045 in Pulmonary Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TX-000045 in Pulmonary Hypertension report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TX-000045 in Pulmonary Hypertension Drug Details: TX-000045 is under development for...
-
Product Insights
NewBroncus Medical Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Broncus Medical Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Broncus Medical Inc (Broncus), formerly Broncus Technologies Inc, is a medical device company that develops navigation, diagnostic and therapeutic technologies for the treatment of patients with lung disease. The company offers Archimedes system, a total lung access platform used for virtual bronchoscopic planning, navigation, and tunneling. It also provides Archimedes Planner, a portable pre-procedure planning and simulation system for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TX-000045 in Cardiovascular Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TX-000045 in Cardiovascular Disease Drug Details: TX-000045 is under development for the treatment of cardiovascular...
-
Company Insights
Innovation and Patenting activity of TX Group AG Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of TX Group AG Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewDiastolic Heart Failure – Drugs In Development, 2024
Empower your strategies with our Diastolic Heart Failure (HFpEF) – Drugs In Development, 2024 report and make more profitable business decisions. Diastolic heart failure, also known as heart failure with preserved ejection fraction, is a condition in which the heart's main pumping chamber becomes stiff and unable to fill properly. One of the two types of left-sided heart failure is diastolic heart failure. Main causes include high blood pressure, diabetes, coronary artery disease, and obesity. Untreated diastolic heart failure has the...
-
Product Insights
NewPeripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs In Development, 2024
Empower your strategies with our Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs In Development, 2024 report and make more profitable business decisions. Peripheral arterial disease (PAD) and peripheral vascular disease (PVD) refer to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh, or calf muscles after activity, such as walking or climbing stairs (intermittent claudication); leg numbness or weakness; coldness in lower leg or foot, especially...
-
Product Insights
NewOcclusive Arterial Disease (OAD) – Drugs In Development, 2024
Empower your strategies with our Occlusive Arterial Disease (OAD) – Drugs In Development, 2024 report and make more profitable business decisions. Occlusive arterial disease (OAD), also known as peripheral arterial disease (PAD) or peripheral vascular disease (PVD), is characterized by the narrowing or blockage of arteries in the extremities, particularly the legs. This occurs due to atherosclerosis, a buildup of plaque made up of cholesterol, fats, calcium, and other substances within the arterial walls. Individuals with OAD may experience symptoms such...
-
Product Insights
NewPeripheral Artery Occlusive Disease (PAOD) – Drugs In Development, 2024
Empower your strategies with our Peripheral Artery Occlusive Disease (PAOD) – Drugs In Development, 2024 report and make more profitable business decisions. Peripheral artery occlusive disease (PAOD), also known as peripheral arterial disease (PAD), refers to a condition characterized by the narrowing or blockage of the arteries outside the heart, predominantly affecting the arteries in the legs. This narrowing occurs due to atherosclerosis, the buildup of plaque within the arterial walls, restricting blood flow to the limbs. Individuals with PAOD may...
-
Product Insights
NewFood Allergy – Drugs In Development, 2024
Empower your strategies with our Food Allergy – Drugs In Development, 2024 report and make more profitable business decisions. Food allergies are immune system reactions to certain proteins in food. Symptoms range from mild itching to severe anaphylaxis, involving difficulty breathing and a drop in blood pressure, which can be life-threatening. Common allergens include peanuts, tree nuts, shellfish, eggs, milk, wheat, and soy. Strict avoidance and preparedness for accidental exposure are crucial. Diagnosis involves tests like skin prick or blood tests,...
-
Product Insights
NewNon Alcoholic Fatty Liver Disease (NAFLD) – Drugs In Development, 2024
Empower your strategies with our Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) – Drugs In Development, 2024 report and make more profitable business decisions. Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Most people with NAFLD experience no signs and symptoms and no complications, but in some people with the disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are...